Phathom Pharmaceuticals (NASDAQ:PHAT) traded higher on Friday after Cantor Fitzgerald initiated its coverage with an overweight recommendation despite a recent selloff attributed to the company's IP ...
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback